Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Randomized trialTirzepatide evidence2022 Tirzepatide Once Weekly for the Treatment of Obesity Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability
(5.1, 13.1) WEGOVY is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
What can help: Your doctor may suggest tapering off Wegovy gradually before starting Contrave to avoid rebound hunger or discomfort
GLP-1 receptor agonists are not licensed specifically as anti-inflammatory agents and prescribing follows diabetes and weight management indications under NICE guidance
Over the next few weeks, we will demystify the GLP-1 and the class of drugs knows as GLP-1 RA
